2. Academic Validation
  3. [Screening of active compounds with myocardial protective effects from Tongmai Yangxin pill]

[Screening of active compounds with myocardial protective effects from Tongmai Yangxin pill]

  • Zhejiang Da Xue Xue Bao Yi Xue Ban. 2015 Mar;44(2):145-53. doi: 10.3785/j.issn.1008-9292.2015.03.005.
Shan Tao 1,  Xin-ying Liang 1,  Yi Wang 2,  Yi Wang 1
Affiliations

Affiliations

  • 1 College of Pharmacy, Zhejiang University, Hangzhou 310058, China;
  • 2 Tianjin Chinese Medical University, Tianjin National Key Laboratory of Modern Chinese Medicine, Tianjin 300193, China;
PMID: 26038132 DOI: 10.3785/j.issn.1008-9292.2015.03.005
Abstract

Objective: Based on cell model and HPLC-MS technology, to screen myocardial protection active compounds from traditional patent medicine Tongmai Yangxin pill (TMYXP).

Methods: Fractions of TMYXP were prepared by high performance liquid preparation technology. The cardioprotective effects of prepared fractions were tested on H2O2 oxidation-damaged H9c2 myocardiocytes. The active components were analyzed by high performance liquid chromatography (HPLC) coupled with high resolution mass spectrometry. The possible active compounds were putatively identified by comparison of their MS ions and molecular weight with literatures.

Results: Ten TMYXP components presented significant myocardial protective activities, 5 of which were investigated and presented good dose-effect relationships. Their median effective concentrations (EC50) were respectively 11.66, 17.44, 13.10, 7.332, 15.15 μg/mL. Totally, 11 potential active compounds were analyzed and identified, including Glycyrrhizic acid, Glycycoumarin, Licoisoflavone, Ophiopogonin D', Licoricon, Gancaonin L, Neoglycyrol, Emodin, Angeloylgomisin H, Angeloylgomisin Q and Glyasperin A.

Conclusion: The myocardial protection active compounds of TMYXP were screened successfully.

Figures
Products